Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 4/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 9/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927706 | 1.00 | ROCK2 (0.38) | ROCK2ROCK1AURKAAURKBKDR | |
| SCHEMBL5031212 | 0.92 | CNR1 (0.37) | ROCK2ROCK1AURKAAURKBKDR | |
| SCHEMBL13927725 | 0.92 | CHEK1 (0.33) | ROCK2ROCK1AURKAAURKBKDR | |
| SCHEMBL5027608 | 0.92 | CHEK1 (0.33) | ROCK2ROCK1AURKAAURKBKDR | |
| SCHEMBL5031136 | 0.91 | LMNA (0.35) | ROCK2ROCK1 | |
| SCHEMBL6427759 | 0.91 | LMNA (0.35) | ROCK2ROCK1 | |
| SCHEMBL5030069 | 0.91 | KCNA3 (0.36) | AURKAKDRCHEK1FGFR1L3MBTL1 | |
| SCHEMBL5030025 | 0.91 | CHEK1 (0.35) | ROCK2ROCK1KDRCHEK1 | |
| SCHEMBL13927740 | 0.90 | CYP1A1 (0.39) | ROCK2ROCK1CYP1A2POLB | |
| SCHEMBL5032392 | 0.90 | CYP1A1 (0.39) | ROCK2ROCK1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | ROCK2 560/4885ROCK1 826/4885AURKA 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.